Preventing Relapse and Recurrence of Depression: A Brief Review of Therapeutic Options

  title={Preventing Relapse and Recurrence of Depression: A Brief Review of Therapeutic Options},
  author={Michael E. Thase},
  journal={CNS Spectrums},
  pages={12 - 21}
  • M. Thase
  • Published 1 December 2006
  • Psychology, Medicine
  • CNS Spectrums
Abstract Depression is increasingly recognized as a highly recurrent and potentially chronic illness that imposes a substantial burden on individuals, families, and society. Evidence indicates that the risks of depressive recurrence, treatment resistance, and chronicity increase as the illness becomes more highly recurrent. Up to 1 year of continuation phase therapy is now recommended for virtually all depressed patients who respond to antidepressants, with a longer course of maintenance phase… 
Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo.
Relapse risk was reduced by both C-CT and fluoxetine in an enriched randomization sampling only CT responders, suggesting that some higher-risk patients may require alternate longer-term interventions.
Maintenance pharmacotherapy for unipolar depression: focus on efficacy
Many evidences are available for an adequate long-term drug treatment of unipolar depression, however, more randomised controlled studies are need to better establish how to manage unipolar patients at high risk of recurrence and to explore the differences in the effectiveness among ADs in the long- term treatment of such patients.
Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors
This is one of the first reports demonstrating a beneficial effect of long-term antidepressant medication on severe relapse rates in naturalistic patients, and may be a proxy marker for treatment resistant and psychotic depression.
First-line pharmacotherapies for depression - what is the best choice?
This review examines the antidepressants that are currently used as the initial or "first-line" therapies for major depressive disorder (MDD), and these newer medications may be grouped into three classes: the selective serotonin reuptake inhibitors, the serotonin and norepinephrine reuptakes inhibitors, and the norpinephrine-dopamine reptake inhibitor.
Tachyphylaxis after Repeated Antidepressant Drug Exposure in Patients with Recurrent Major Depressive Disorder
The hypothesis that tachyphylaxis may develop after repeated antidepressant drug trials supports the hypothesis that an increase in prior antidepressants exposure is associated with a reduced responsiveness to sertraline therapy.
SSRIs vs. SNRIs: personalized treatment of depression and decision algorithms for choosing antidepressant medications
Introduction Major Depressive Disorder (MDD) is a major cause of morbidity worldwide. Lifetime prevalence varies widely by country, and is estimated around 17% in the United States. MDD is currently
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines
These guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing and management, next-step treatment, relapse prevention, treatment of relapse and stopping treatment.


Preventing relapse/recurrence in recurrent depression with cognitive therapy: a randomized controlled trial.
Augmenting treatment as usual with CT resulted in a significant protective effect, which intensified with the number of previous depressive episodes experienced, extending the accumulating evidence that cognitive interventions following remission can be useful in preventing relapse/recurrence in patients with recurrent depression.
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years.
In geriatric patients with recurrent major depression, maintenance treatment with nortriptyline or IPT is superior to placebo in preventing or delaying recurrence and combined treatment using both appears to be the optimal clinical strategy in preserving recovery.
Prevention of relapse following cognitive therapy vs medications in moderate to severe depression.
Cognitive therapy has an enduring effect that extends beyond the end of treatment and seems to be as effective as keeping patients on medication.
Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial.
Maintenance therapy with sertraline is well tolerated and has significant efficacy in preventing recurrence or reemergence of depression in chronically depressed patients.
Five-year outcome for maintenance therapies in recurrent depression.
It is concluded that active imipramine treatment is an effective means of preventing recurrence beyond 3 years and that patients with previous episodes less than 2 1/2 years apart, therefore, merit continued prophylaxis for at least 5 years.
The prophylaxis of depressive episodes in recurrent depression following discontinuation of drug therapy: integrating psychological and biological factors
The key finding is that high specificity is of significant prophylactic benefit even for patients with a biological vulnerability for recurrence, and high treatment specificity is, in turn, reflected in longer times to recurrence.
Three-year outcomes for maintenance therapies in recurrent depression.
It is concluded that active imipramine hydrochloride maintained at an average dose of 200 mg is an effective means of preventing recurrence and that monthly interpersonal psychotherapy serves to lengthen the time between episodes in patients not receiving active medication.
Predictors of relapse in a prospective study of fluoxetine treatment of major depression.
The pattern of response to acute treatment appears to be inconsistently predictive of relapse, and there is a high rate of relapse with both active medication and placebo in patients with chronic depression.